HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
piroximone
structure in first source
Also Known As:
4-ethyl-1,3-dihydro-5-(4-pyridinylcarbonyl)-2H-imidazol-2-one; MDL 19,205; MDL 19205; MDL-19,205; MDL-19205
Networked:
30
relevant articles (
7
outcomes,
5
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azoles: 2138
Imidazoles: 150
piroximone: 30
Related Diseases
1.
Heart Failure
10/01/1987 - "
Thus, piroximone may prove useful in the long-term management of chronic cardiac failure.
"
11/01/1987 - "
Thus, long-term treatment with piroximone was not associated with an improvement in maximal and submaximal exercise capacity in patients with congestive heart failure.
"
01/01/1984 - "
The pharmacological profile revealed by these and other studies suggests that MDL 19205 should be useful in the clinical treatment of congestive heart failure.
"
10/01/1995 - "
[Acute hemodynamic effects of piroximone i.v. in patients with severe heart failure].
"
05/01/1994 - "
Effects of piroximone on the right ventricular function in severe heart failure patients.
"
2.
Stroke (Strokes)
01/01/1986 - "
Cardiac index was increased less by SN (15%) than piroximone (48%) (p less than 0.001), and stroke work index significantly enhanced only by piroximone (p less than 0.001).
"
05/01/1987 - "
The increase in stroke work index with a concomitant decrease in left ventricular filling pressure indicates an improvement in systolic performance after treatment with piroximone.
"
3.
Chemical and Drug Induced Liver Injury
11/01/1987 - "
Seven of the 10 patients completed 12 weeks of therapy with piroximone; one patient withdrew after 8 weeks because of deterioration in clinical status; one developed severe ventricular arrhythmias and died after 5 days of treatment; and a drug-induced hepatitis was documented in one subject at 4 weeks.
"
4.
Renal Insufficiency (Renal Failure)
02/01/1995 - "
Pharmacokinetics of piroximone after oral and intravenous administration to patients with renal insufficiency.
"
02/01/1995 - "
The pharmacokinetics of piroximone (PI) were determined in patients with renal failure (inulin clearance less than 50 ml min-1 per 1.73 m2) using two protocols: (a) 10 patients received a single i.v. infusion of 0.5 mg kg-1 PI and the data were compared with those from seven healthy subjects receiving the same regimen; (b), a single oral dose of either 25 or 50 mg PI was given to 20 patients.
"
5.
Ventricular Premature Complexes (Premature Ventricular Contraction)
03/01/1993 - "
Serial assessment of hemodynamics, plasma piroximone levels, and ventricular ectopic beats was performed.
"
Related Drugs and Biologics
1.
Vasodilator Agents (Vasodilators)
2.
Dobutamine
3.
Ouabain (G Strophanthin)
4.
Hydralazine (Apresoline)
5.
Nitroglycerin (Dynamite)
6.
Furosemide (Lasix)
7.
piroximone
8.
Phosphodiesterase Inhibitors
9.
Epoprostenol (Prostacyclin)
10.
Enoximone
Related Therapies and Procedures
1.
Therapeutics
2.
Aftercare (After-Treatment)
3.
Intravenous Administration
4.
Intravenous Infusions
5.
Regimen B